ERAS

ERAS is exhibiting textbook 'Institutional Absorption' following its successful $225M capital raise at $10.00, which effectively reset the floor and removed financing overhang. The stock's +23% relative strength is fueled by a 'RAS Renaissance' narrative, validated by early ERAS-0015 clinical data and a cluster of analyst upgrades (targets raised to $15). While the broad market frets over geopolitical tension, ERAS is trading on idiosyncratic catalysts, specifically the anticipation of topline monotherapy data in H1 2026. The current -2% dip is likely healthy consolidation above the deal price, offering a tactical entry within a confirmed 'Rocket Ship' uptrend.